1 Study Matches
Site for A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 68 week study with phone call 20 weeks after last dose. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if risankizumab is beneficial and well tolerated in patients with HS. Each subject will be assigned to 1 of 3 treatment groups, reassigned to a different treatment at week 16, and then receive risankizumab at week 20.
18 year(s) or older
Inclusion Criteria:Moderate to Severe HS for at least 1 year
HS lesions in at least 2 affected areas
Willing to follow all study instructions
Exclusion Criteria:Certain treatments for HS are not allowed; coordinator will discuss specific treatments
unable or unwilling to return to the study site for all study visits and tests.
Known Hepatitis B, Hepatitis C, or HIV infections